Blood Advances · 2019 · 10 citations · 10 references
MedicineImmunologyOncologyImmunopharmacologyImmunotherapyMonoclonal AntibodiesCancer ImmunotherapyHematologic Malignancy TherapyLeptomeningeal DiseaseMonoclonal Antibody TherapyTargeted TherapyAlemtuzumab UseT-cell Malignancy Therapy
Key Points This is the first report of successful treatment of therapy-resistant leptomeningeal T-PLL with intrathecal alemtuzumab. Intrathecal alemtuzumab is a potentially safe and efficacious therapeutic alternative for treatment of leptomeningeal T-PLL.
10
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
G Hale, Mike Clark, R. Marcus et al. · The Lancet · 1988 · 692 citations
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
Claire Dearden, Estella Matutes, Bruno Cazin et al. · Blood · 2001 · 317 citations · Full text
Medicine, Hematology, Oncology +8
Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Rachel Pawson, Martin J.S. Dyer, R M Y Barge et al. · Journal of Clinical Oncology · 1997 · 210 citations
Medicine, Hematology, Oncology +17